2018 American Transplant Congress
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies
Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…2018 American Transplant Congress
Pediatric Kidney Transplant in Norway – Results after Switching from Midline to Retroperitoneal Approach in Recipients below 25 kg
Section for Transplant Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Introduction: Pediatric kidney transplants demand a high level of surgical and medical involvement and skill. In Norway, all organ transplants are centralized and performed at…2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…2018 American Transplant Congress
Radiation Exposure to the Transplant Surgeon: A Case Study of Recent Yttrium-90 Treatment in an Explanted Liver
BACKGROUND: Yttrium-90 (Y-90) radioembolization for the treatment of hepatocellular carcinoma can present safety challenges to the surgeon when transplanting a recently treated Y-90 patient. To…2018 American Transplant Congress
The First Series of Ischemia-Free Liver Transplantation in Human
BACKGROUND&AIMS: Ischemia and reperfusion injury (IRI) is known as an inevitable event leading to early and late graft failure. We have performed the first case…2018 American Transplant Congress
Efficacy and Safety of Immediate- and Prolonged-Release Tacrolimus in De Novo Pediatric Transplantation: Randomized Study
This study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) vs immediate-release tacrolimus (IR-T) in de novo pediatric transplant pts. Phase II, parallel-group, multicenter, open-label study…2018 American Transplant Congress
Reducing No-Show Rate and Filling Cancelled Appointments: Multi-Faceted Interventions Markedly Reduced Time to Kidney Transplant Evaluation
Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA.
Introduction: Time from referral to appointment for kidney transplant evaluation is an important metric. Demands of dialysis schedules and transportation logistics typically lead to high…2018 American Transplant Congress
Procurement Travel Safety: Current Practices, Accident Frequency, Perceptions of Safety and Means to Reduce Risk
Emory Transplant Center, Emory University, Atlanta, GA.
Transplant procurement teams travel extensively. Though considered hazardous, little data on the necessity and risks of this travel exist. We conducted a survey of ASTS…2018 American Transplant Congress
Medication Reconciliation in Abdominal Transplantation
Medication adherence post transplantation is vital. Upon discharge, abdominal transplant patients receive a medication list from the electronic medical record (EMR) and obtain a medication…2018 American Transplant Congress
12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…
- 1
- 2
- 3
- …
- 8
- Next Page »